首页> 美国卫生研究院文献>BMJ Open >Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL a prospective randomised head-to-head study

【2h】

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL a prospective randomised head-to-head study

机译：Natalizumab与Fingolimod用于有效复发 - 延髓多发性硬化症：结果来自揭示一项潜在随机的头脑研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

To directly compare the efficacy of natalizumab and fingolimod in patients with active relapsing-remitting multiple sclerosis.

机译：直接比较Natalizumab和Fingolimod在患者中延迟复发延迟多发性硬化症的疗效。

著录项

期刊名称 BMJ Open
作者
Helmut Butzkueven; Stephanie Licata; Douglas Jeffery; Douglas L Arnold; Massimo Filippi; Jeroen JG Geurts; Sourav Santra; Nolan Campbell; Pei-Ran Ho;
展开▼
作者单位

展开▼
年(卷),期 2020(10),10
年度 2020
页码 e038861
总页数 6
原文格式 PDF
正文语种
中图分类
关键词
neurology; multiple sclerosis; clinical trials;

机译：神经病学;多发性硬化;临床试验;

相似文献

外文文献
中文文献
专利

1. THE RAPID EFFICACY OF NATALIZUMAB VS FINGOLIMOD IN PATIENTS WITH ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): RESULTS FROM REVEAL, A RANDOMISED, HEAD-TO-HEAD STUDY [J] . Butzkueven Helmut, Jeffery Douglas, Arnold Douglas L., Journal of Neurology, Neurosurgery and Psychiatry . 2018,第6期

机译：Natalizumab VS Fingolimod在患有活性复发延迟多发性硬化症（RRMS）的患者中的快速疗效：结果来自揭示，随机的头部到头研究
2. Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study [J] . S. Licata, H. Butzkueven, D. Jeffery, Journal of the Neurological Sciences: Official Bulletin of the World Federation of Neurology . 2017,第期

机译：Natalizumab与Fingolimod患者有活性复发 - 延长多发性硬化症（RRMS）：来自揭示，随机的头部到头期4研究的疾病活动的比较MRI评估
3. Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis [J] . Kalincik Tomas, Horakova Dana, Spelman Tim, Annals of neurology . 2015,第3期

机译：在主动复发-缓解型多发性硬化症患者中转用纳他珠单抗与芬戈莫德
4. Microstructural Modulations in the Hippocampus Allow to Characterizing Relapsing-Remitting Versus Primary Progressive Multiple Sclerosis [C] . Lorenza Brusini, Ilaria Boscolo Galazzo, Muge Akinci, International Workshop on Brain-Lesion;Medical Image Computing and Computer Assisted Intervention Conference . 2020

机译：海马中的微观结构调制允许表征复发 - 延长与初级进步多发性硬化
5. An investigation of early relapsing-remitting multiple sclerosis patients using diffusion tensor imaging and spectroscopy. [D] . Zaini, Wan Hazlin. 2013

机译：使用扩散张量成像和光谱法对早期复发缓解型多发性硬化症患者进行调查。
6. The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials [O] . Georgios Tsivgoulis, Aristeidis H. Katsanos, Dimitris Mavridis, -1

机译：纳他珠单抗与芬戈莫德治疗复发缓解型多发性硬化症的疗效：系统评价随机安慰剂对照试验的间接证据和观察性头对头试验的荟萃分析。
7. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study [O] . Helmut Butzkueven, Stephanie Licata, Douglas Jeffery, 2020

机译：Natalizumab与Fingolimod用于有效复发 - 延髓多发性硬化症：结果来自揭示，一项潜在随机的头脑研究

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL a prospective randomised head-to-head study

摘要

著录项

相似文献

相关主题

期刊订阅